Clinical study on levofloxacin for prostatitis and cytokines in urine or expressed prostatic secretion of prostatitis patients

Abstract

The clinical efficacy and safety of levofloxacin (LVFX) were evaluated in 19 patients with acute bacterial, chronic bacteirial or chronic non-bacterial prostatitis (ABP, CBP, CNP). We measured urinary cytokines (tumor necrosis factor, TNF-α, interleukin 1β, IL-β, interleukin 6 IL-6, interleukin 8, IL-8) before and after the treatment.LVFX was given to ABP patients at dose of 200-300 mg per day for 14 days and to CBP and CNP at a dose of 100-300 mg per day for 28 days.Efficacy rate for ABP was 6/6 on 7 days by UTI criteria. While that of CBP was 4/9 on 14 day. WBC improved rate of CNP was 3/4 on 14 day. The levels of all cytokines of ABP group and that of IL-1β in CBP group higher than those of control.The levels of TNF-α of ABP after treatment decreased compare with those before treatment significantly.